Because both HDAC and DNMT inhibitors help increase gene expression, they are potential candidates for treating NPC; they may upregulate the expression of NPC1, NPC2, Rabs, or, more broadly, other factors that contribute to the management of intracellular cholesterol levels. Here, NPC1 is linked to nasopharyngeal carcinoma.